GFRAL antagonistic antibodies with improved affinity and uses thereof

Abstract

The present invention relates to GFRAL antagonistic antibodies having improved affinity and uses thereof, and more specifically, the present invention relates to anti-GFRAL antibodies having improved affinity or antigen-binding fragments thereof, comprising a heavy chain CDR and a light chain CDR of specific sequences. The anti-GFRAL antibody having improved affinity exhibits a higher binding capacity to GFRAL protein than a conventional anti-GFRAL antibody, and thus is expected to be effectively used for improving or treating cancer-related anorexia or cachexia syndrome and side effects of chemotherapy anti-cancer drugs.